Table 3.
Global differences in patient disease status and comorbid factors across the 10 Clusters
| Cluster | Test statistic | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ||
| Patient Disease Status: | |||||||||||
| Non-CRS controls (N = 70; 35.4%) | 4 (33.3%) | 1 (6.7%) | 27 (64.3%) | 34 (91.9%) | 3 (15.0%) | 1 (3.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ꭕ2=178.64** |
| CRSsNP (N = 53; 26.8%) | 6 (50.0%) | 0 (0.0%) | 12 (28.6%) | 3 (8.1%) | 6 (30.0%) | 14 (50.0%) | 4 (50.0%) | 5 (31.3%) | 2 (40.0%) | 1 (6.7%) | |
| CRSwNP (N = 75; 37.9%) | 2 (16.7%) | 14 (93.3%) | 3 (7.1%) | 0 (0.0%) | 11 (55.0%) | 13 (46.4%) | 4 (50.0%) | 11 (68.8%) | 3 (60.0%) | 14 (93.3%) | |
| Comorbidity: | |||||||||||
| No Asthma (N = 140; 70.7%) | 10 (83.3%) | 6 (40.0%) | 36 (85.7%) | 34 (91.9%) | 15 (75.0%) | 12 (42.9%) | 7 (87.5%) | 9 (56.3%) | 4 (80.0%) | 7 (46.7%) | ꭕ2=38.78** |
| Asthma (N = 58; 29.3%) | 2 (16.7%) | 9 (60.0%) | 6 (14.3%) | 3 (8.1%) | 5 (25.0%) | 16 (57.1%) | 1 (12.5%) | 7 (43.8%) | 1 (20.0%) | 8 (53.5%) | |
| No allergic rhinitis / response (N = 113; 57.1%) | 9 (75.0%) | 6 (40.0%) | 24 (57.1%) | 29 (78.4%) | 10 (50.0%) | 13 (46.4%) | 5 (62.5%) | 8 (50.0%) | 3 (60.0%) | 3 (20.0%) | ꭕ2=21.45* |
| Allergic rhinitis / response (N = 85; 42.9%) | 3 (25.0%) | 9 (60.0%) | 18 (42.9%) | 8 (21.6%) | 10 (50.0%) | 15 (53.6%) | 3 (37.5%) | 8 (50.0%) | 2 (40.0%) | 12 (80.0%) | |
| Not Current Smoker (N = 189; 95.5%) | 12 (100%) | 15 (100%) | 38 (90.5%) | 36 (97.3%) | 17 (85.0%) | 28 (100%) | 7 (87.5%) | 16 (100%) | 5 (100%) | 15 (100%) | ꭕ2= 14.68 |
| Current Smoker (N = 9; 4.5%) | 0 (0.0%) | 0 (0.0%) | 4 (9.5%) | 1 (2.7%) | 3 (15.0%) | 0 (0.0%) | 1 (12.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| No Diabetes (N = 179; 90.4%) | 11 (97.7%) | 14 (93.3%) | 39 (92.9%) | 34 (91.9%) | 18 (90.0%) | 25 (89.3%) | 7 (87.5%) | 13 (81.3%) | 5 (100%) | 13 (86.7%) | ꭕ2= 15.25 |
| Insulin Dependent Diabetes (N = 8; 4.0%) | 1 (8.3%) | 0 (0.0%) | 1 (2.4%) | 1 (2.7%) | 2 (10.0%) | 2 (7.1%) | 1 (12.5%) | 0 (0.0%) | 0 (0.0%) | 1 (6.7%) | |
| Non-Insulin Dependent Diabetes (N = 11, 5.6%) | 0 (0.0%) | 1 (6.7%) | 2 (4.8%) | 2 (5.4%) | 0 (0.0%) | 1 (3.6%) | 0 (0.0%) | 3 (18.8%) | 0 (0.0%) | 1 (6.7%) | |
| No GERD (N = 157; 79.3%) | 9 (75.0%) | 10 (66.7%) | 33 (78.6%) | 34 (91.9%) | 18 (90.0%) | 20 (71.4%) | 5 (62.5%) | 13 (81.3%) | 5 (100%) | 10 (66.7%) | ꭕ2=13.29 |
| GERD (N = 41; 20.7%) | 3 (25.0%) | 5 (33.3%) | 9 (21.4%) | 3 (8.1%) | 2 (10.0%) | 8 (28.6%) | 3 (37.5%) | 3 (18.8%) | 0 (0.0%) | 5 (33.3%) | |
| Overall (N = 198) | N=12 | N=15 | N=42 | N=37 | N=20 | N=28 | N=8 | N=16 | N=5 | N=15 | |
Percentages (in parentheses) are relative to the total number of patients in that cluster. CRS, chronic rhinosinusitis; GERD, gastroesophageal reflux disease. CRSsNP, chronic rhinosinusitis without nasal polyposis; CRSwNP, chronic rhinosinusitis with nasal polyposis; ꭕ2, chi-square test statistic.